Publicacións nas que colabora con P. Coto-Segura (16)

2024

  1. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  2. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

2020

  1. Dermatologists’ Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 10, pp. 835-846

  2. Linguistic and Cultural Adaptation to Spanish of the Screening Tool Psoriatic Arthritis UnclutteRed Screening Evaluation (PURE4)

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 8, pp. 655-664

2019

  1. NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis

    Molecular Diagnosis and Therapy, Vol. 23, Núm. 5, pp. 627-633

2018

  1. IL17RA gene variants and anti-TNF response among psoriasis patients

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 76-80

2017

  1. NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant

    Human Immunology, Vol. 78, Núm. 5-6, pp. 435-440

2016

  1. Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis

    British Journal of Dermatology, Vol. 175, Núm. 1, pp. 134-141

2015

  1. Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort

    Journal of Dermatological Science, Vol. 80, Núm. 2, pp. 111-115

  2. Association between the IL17RA rs4819554 polymorphism and reduced renal filtration rate in the Spanish RENASTUR cohort

    Human Immunology, Vol. 76, Núm. 2-3, pp. 75-78

  3. CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients

    International Immunopharmacology, Vol. 29, Núm. 2, pp. 947-949

  4. Cardiovascular risk factors influence response to biological therapies in psoriasis

    Journal of the American Academy of Dermatology, Vol. 73, Núm. 2, pp. 327-329

  5. Influence of Fcγ receptor polymorphisms on response to anti-tumor necrosis factor treatment in psoriasis

    JAMA Dermatology

  6. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients

    Pharmacogenetics and Genomics, Vol. 25, Núm. 6, pp. 313-316

  7. The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients

    Archives of Dermatological Research, Vol. 307, Núm. 5, pp. 405-412